What is the 13F Pro Quality Score for IMDX?

13F Pro ranks Insight Molecular Diagnostics Inc. (IMDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IMDX's current score at https://13fpro.ai/research/IMDX (free sign-up required for the full ranking).

Which hedge funds own the most IMDX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of IMDX include BROADWOOD CAPITAL, AWM Investment Company,, PURA VIDA INVESTMENTS,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/IMDX as soon as new 13F filings post.

Where does 13F Pro source IMDX data?

All Insight Molecular Diagnostics Inc. fundamentals and ownership data come directly from SEC EDGAR. Insight Molecular Diagnostics Inc. files with the SEC under CIK 1642380. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IMDX in?

Insight Molecular Diagnostics Inc. (IMDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IMDX research updated on 13F Pro?

IMDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Insight Molecular Diagnostics Inc.(IMDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1642380 IMDX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $4.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IMDX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Insight Molecular Diagnostics Inc. (IMDX), a Healthcare sector company. IMDX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $4.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Insight Molecular Diagnostics Inc. reports quarterly revenue of $32.0K, net income of $-4.3M, free cash flow of $-8.3M. Top institutional holders of IMDX by reported 13-F value include BROADWOOD CAPITAL, AWM Investment Company,, PURA VIDA INVESTMENTS,, based on the most recent SEC filings. IMDX trades on the Nasdaq exchange and files with the SEC under CIK 1642380. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Insight Molecular Diagnostics Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$32.0K

Net Income

Q1 2026

$-4.3M

Free Cash Flow

Q1 2026

$-8.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+115.6% YoY

$4.1MFY 2025

FY21 $2.2MFY23 $1.5MFY24 $1.9MFY25 $4.1M

Net Income

+17.2% YoY

$-50.2MFY 2025

FY21 $-64.1MFY23 $-27.8MFY24 $-60.7MFY25 $-50.2M

Operating Income

+16.2% YoY

$-51.1MFY 2025

FY21 $-53.7MFY23 $-25.1MFY24 $-61.0MFY25 $-51.1M

EPS (Diluted)

+64.6% YoY

$-1.65FY 2025

FY21 —FY23 $-3.75FY24 $-4.66FY25 $-1.65

Total Assets

-26.6% YoY

$25.8MFY 2025

FY21 $159.6MFY23 $74.9MFY24 $35.1MFY25 $25.8M

Op. Cash Flow

-7.2% YoY

$-22.2MFY 2025

FY21 $-35.9MFY23 $-23.3MFY24 $-20.7MFY25 $-22.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018
Revenue	$4.1M +115.6%	$1.9M +25.1%	$1.5M -31.6%	$2.2M	—	—
Net Income	$-50.2M +17.2%	$-60.7M -118.4%	$-27.8M +56.7%	$-64.1M -185.8%	$-22.4M -42.4%	$-15.8M
Operating Income	$-51.1M +16.2%	$-61.0M -142.8%	$-25.1M +53.2%	$-53.7M -141.6%	$-22.2M -46.3%	$-15.2M
EPS (Diluted)	$-1.65 +64.6%	$-4.66 -24.3%	$-3.75	—	—	—
Total Assets	$25.8M -26.6%	$35.1M -53.2%	$74.9M -53.1%	$159.6M +300.3%	$39.9M +318.8%	$9.5M
Operating Cash Flow	$-22.2M -7.2%	$-20.7M +11.3%	$-23.3M +35.1%	$-35.9M -82.3%	$-19.7M -69.2%	$-11.6M

AI Insight: IMDX Financial Trends

IMDX remains pre-revenue with persistent operating losses and eroding equity; no path to profitability evident.

• Revenue has collapsed to $0–$2M quarterly across 8 quarters; Q1 2026 at $0M marks lowest level since Q2 2024.

• Operating losses average $11M per quarter with no trend toward breakeven; Q4 2025 loss of $23M was heaviest.

• Equity has deteriorated from $23M (Q2 2024) to negative $11M (Q1 2026); company now technically insolvent on book value.

⚠ Operating cash burn remains stable at $5–$8M per quarter with no sign of deceleration despite minimal revenue.

⚠ Q4 2025 loss of $23M and subsequent equity swing suggest potential writedowns or one-time charges; near-term solvency risk.

AI Insight: IMDX Ratio Trends

IMDX remains deeply unprofitable with ROA oscillating between -42% and -99% across nine quarters; no path to profitability visible in available data.

• ROA deteriorated sharply to -98.8% in Q3 2025, the worst reading in the dataset, before recovering only partially to -42.4% in Q1 2026.

• Q1 2026 ROA of -42.4% remains deeply negative and offers no evidence of fundamental operational improvement despite volatility.

⚠ Absence of OpMargin, NPM, ROE, ROIC, and D/E data limits visibility into profitability drivers, leverage, and equity quality.

⚠ Q3 2025 collapse to -98.8% ROA suggests either a one-time charge or structural cash-burn acceleration requiring urgent clarification.

Get alerted when IMDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Insight Molecular Diagnostics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IMDX

BROADWOOD CAPITAL INC
$39.1M11,931,839 sh
AWM Investment Company, Inc.
$9.2M2,806,256 sh
PURA VIDA INVESTMENTS, LLC
$3.1M947,134 sh
Alyeska Investment Group, L.P.
$2.8M840,777 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.8M537,161 sh
HEIGHTS CAPITAL MANAGEMENT, INC
$1.3M392,545 sh
GEODE CAPITAL MANAGEMENT, LLC
$860.2K262,053 sh
BlackRock, Inc.
$443.9K135,345 sh
VANGUARD FIDUCIARY TRUST CO
$434.9K132,591 sh
Family Office Research LLC
$417.4K127,266 sh

Fund	Value	Shares
BROADWOOD CAPITAL INC	$39.1M	11,931,839
AWM Investment Company, Inc.	$9.2M	2,806,256
PURA VIDA INVESTMENTS, LLC	$3.1M	947,134
Alyeska Investment Group, L.P.	$2.8M	840,777
VANGUARD CAPITAL MANAGEMENT LLC	$1.8M	537,161
HEIGHTS CAPITAL MANAGEMENT, INC	$1.3M	392,545
GEODE CAPITAL MANAGEMENT, LLC	$860.2K	262,053
BlackRock, Inc.	$443.9K	135,345
VANGUARD FIDUCIARY TRUST CO	$434.9K	132,591
Family Office Research LLC	$417.4K	127,266

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IMDX on your watchlist

Track score changes the day Insight Molecular Diagnostics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IMDX a good stock to buy?

13F Pro's AI-powered analysis of Insight Molecular Diagnostics Inc. (IMDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMDX are available on the IMDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IMDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Insight Molecular Diagnostics Inc.'s investment landscape.